Bristol Myers Squibb Share Holder Equity 2010-2022 | BMY

Bristol Myers Squibb share holder equity from 2010 to 2022. Share holder equity can be defined as the sum of preferred and common equity items
  • Bristol Myers Squibb share holder equity for the quarter ending June 30, 2022 was $32.661B, a 11.43% decline year-over-year.
  • Bristol Myers Squibb share holder equity for 2021 was $36.006B, a 4.95% decline from 2020.
  • Bristol Myers Squibb share holder equity for 2020 was $37.882B, a 26.72% decline from 2019.
  • Bristol Myers Squibb share holder equity for 2019 was $51.698B, a 265.95% increase from 2018.
Bristol Myers Squibb Annual Share Holder Equity
(Millions of US $)
2021 $36,006
2020 $37,882
2019 $51,698
2018 $14,127
2017 $11,847
2016 $16,347
2015 $14,424
2014 $14,983
2013 $15,236
2012 $13,638
2011 $15,867
2010 $15,638
2009 $14,785
Bristol Myers Squibb Quarterly Share Holder Equity
(Millions of US $)
2022-06-30 $32,661
2022-03-31 $31,645
2021-12-31 $36,006
2021-09-30 $37,284
2021-06-30 $36,874
2021-03-31 $37,673
2020-12-31 $37,882
2020-09-30 $50,230
2020-06-30 $49,160
2020-03-31 $49,977
2019-12-31 $51,698
2019-09-30 $17,754
2019-06-30 $16,151
2019-03-31 $15,317
2018-12-31 $14,127
2018-09-30 $13,750
2018-06-30 $12,418
2018-03-31 $12,906
2017-12-31 $11,847
2017-09-30 $14,914
2017-06-30 $14,821
2017-03-31 $14,535
2016-12-31 $16,347
2016-09-30 $15,781
2016-06-30 $15,078
2016-03-31 $14,551
2015-12-31 $14,424
2015-09-30 $15,273
2015-06-30 $15,291
2015-03-31 $15,689
2014-12-31 $14,983
2014-09-30 $15,201
2014-06-30 $15,379
2014-03-31 $15,531
2013-12-31 $15,236
2013-09-30 $14,714
2013-06-30 $14,373
2013-03-31 $13,699
2012-12-31 $13,638
2012-09-30 $13,900
2012-06-30 $15,812
2012-03-31 $16,246
2011-12-31 $15,867
2011-09-30 $16,436
2011-06-30 $16,145
2011-03-31 $15,901
2010-12-31 $15,638
2010-09-30 $15,857
2010-06-30 $15,574
2010-03-31 $15,233
2009-12-31 $14,785
2009-09-30 $14,371
2009-06-30 $13,936
2009-03-31 $13,129
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $150.984B $46.385B
Bristol-Myers Squibb is a one of the leading global specialty biopharmaceutical companies focused on the development of treatments targeting serious diseases like cancer, inflammatory, immunologic, cardiovascular or fibrotic diseases. Backed by its blockbuster immuno-oncology drug, Opdivo, Bristol-Myers has a strong oncology portfolio, comprising other drugs like Revlimid, Pomalyst, Sprycel, Yervoy and Empliciti. It also has important immunology and cardiovascular drugs like Orencia and Eliquis. It's experiencing growth in both the Eliquis brand and the market, while also advancing its Factor XIa inhibitor program. After the sale of the global Diabetes business to AstraZeneca and the discontinuation of discovery research efforts in virology, it's focusing solely on research in core therapeutic areas like oncology, immuno-oncology, immunoscience, cardiovascular, fibrosis and genetically defined diseases. It acquried Celgene Corporation and MyoKardia. It received regulatory approvals for Reblozyl and Inrebic.
Stock Name Country Market Cap PE Ratio
GSK (GSK) United Kingdom $59.709B 7.17
Bio-Rad Laboratories (BIO.B) United States $12.433B 27.47
Biohaven Pharmaceutical Holding (BHVN) United States $10.873B 0.00
QIAGEN (QGEN) Netherlands $9.383B 15.71
Ginkgo Bioworks Holdings (DNA) United States $4.998B 0.00
Arcus Biosciences (RCUS) United States $1.819B 35.51
Myovant Sciences (MYOV) United Kingdom $1.614B 0.00
Emergent Biosolutions (EBS) United States $1.040B 6.03
ADC Therapeutics SA (ADCT) Switzerland $0.376B 0.00
Zymeworks (ZYME) Canada $0.305B 0.00
Enzo Biochem (ENZ) United States $0.105B 0.00
Gelesis Holdings (GLS) United States $0.081B 0.00
SQZ Biotechnologies (SQZ) United States $0.068B 0.00
Ambrx Biopharma (AMAM) United States $0.041B 0.00